banner USF Home College of Arts & Sciences OASIS myUSF USF A-Z Index

USF Home > College of Arts and Sciences > Cancer Biology Ph.D. Program

Vito  Rebecca

Vito Rebecca

Vito Rebecca

  

Bio

fiogf49gjkf0d
On March 19, 2014, Dr. Vito Rebecca successfully defended his dissertation. Pictured with is committee (l to r): Lori Hazlehurst, Srikumar Chellappan, Major Professor Keiran Smalley, Vito, invited chair Ravi Amaravadi, M.D. from Perelman School of Medicine UPenn and Sandy Anderson. Dr. Rebecca has accepted a postdoc position with Dr. Amaravadi.

Dr. Rebecca's publication record while in the Program:

Rebecca VW, Smalley KS. Change or die: targeting adaptive signaling to kinase inhibition in cancer cells. Biochem Pharmacol. 2014 Oct 15;91(4):417-25. doi: 10.1016/j.bcp.2014.07.031. Epub 2014 Aug 12. Review. PMID: 25107706

Rebecca VW, Alicea GM, Paraiso KH, Lawrence H, Gibney GT, Smalley KS. Vertical inhibition of the MAPK pathway enhances therapeutic responses in NRAS-mutant melanoma. Pigment Cell Melanoma Res. 2014 Nov;27(6):1154-8. doi: 10.1111/pcmr.12303. Epub 2014 Sep 1. PMID: 25130256

Rebecca VW, Wood ER, Fedorenko IV, Paraiso KH, Haarberg HE, Chen Y, Xiang Y, Sarnaik A, Gibney GT, Sondak VK, Koomen JM, Smalley KS. Evaluating Melanoma Drug Response and Therapeutic Escape with Quantitative Proteomics. Mol Cell Proteomics. 2014 Apr 23.PMID:24760959

Rebecca VW, Massaro RR, Fedorenko IV, Sondak VK, Anderson AR, Kim E, Amaravadi RK, Maria-Engler SS, Messina JL, Gibney GT, Kudchadkar RR, Smalley KS. Inhibition of autophagy enhances the effects of the AKT inhibitor MK-2206 when combined with paclitaxel and carboplatin in BRAF wild-type melanoma.Pigment Cell Melanoma Res. 2014 May;27(3):465-78. PMID:24490764

Kim E, Rebecca V, Fedorenko IV, Messina JL, Mathew R, Maria-Engler SS, Basanta D, Smalley KS, Anderson AR. Senescent fibroblasts in melanoma initiation and progression: an integrated theoretical, experimental, and clinical approach.Cancer Res. 2013 Dec 1;73(23):6874-85.PMID:24080279

Haarberg HE, Paraiso KH, Wood E, Rebecca VW, Sondak V, Koomen JM, Smalley KS. Inhibition of Wee1, AKT and CDK4 following treatment with the HSP90 inhibitor XL888 in NRAS mutant melanoma. Mol Cancer Ther. 2013 Mar 28.

Rebecca, Vito W; Sondak, Vernon K; Smalley, Keiran S.M.A brief history of melanoma: from mummies to mutations.Melanoma Research:April 2012 - Volume 22 - Issue 2 - p 114–122.

John JK, Paraiso KH, Rebecca VW, Cantini LP, Abel EV, Pagano N, Meggers E, Mathew R, Krepler C, Izumi V, Fang B, Koomen JM, Messina JL, Herlyn M, Smalley KS. GSK3ß Inhibition Blocks Melanoma Cell/Host Interactions by Downregulating N-Cadherin Expression and Decreasing FAK Phosphorylation.J Invest Dermatol. 2012 Jul 19. doi: 10.1038/jid.2012.237.

Paraiso KH, Haarberg E, Wood E, Rebecca VW, Chen YA, Xiang Y, Ribas A, Lo RS, Weber JS, Sondak VK, John J, Sarnaik AA, Koomen J, Smalley KS. The HSP-90 inhibitor XL888 overcomes BRAF inhibitor resistance mediated through diverse mechanisms.Clin Cancer Res. 2012 Feb 20.

Rebecca VW, Smalley KS.Tumor heterogeneity and strategies to overcome kinase inhibitor resistance in cancer: lessons from melanoma.Expert Opin Investig Drugs. 2011 Feb;20(2):137-40.

Paraiso KH, Xiang Y, Rebecca VW, Abel EV, Chen YA, Munko AC, Wood E, Fedorenko IV, Sondak VK, Anderson AR, Ribas A, Palma MD, Nathanson KL, Koomen JM, Messina JL, Smalley KS.PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression.Cancer Res. 2011 Apr 1;71(7):2750-60

Flach EH, Rebecca VW, Herlyn M, Smalley KS, Anderson AR.Fibroblasts contribute to melanoma tumor growth and drug resistance.Mol Pharm. 2011 Dec 5;8(6):2039-49.

Dr. Rebecca's publication record since graduation:

Rebecca VW, Amaravadi RK. Emerging strategies to effectively target autophagy in cancer. Oncogene.2016 Jan 7;35(1):1-11. PMID: 25893285